Abstract Treatment of tuberculosis (TB) involves the administration of anti-mycobacterial
drugs for several months. The emergence of drug-resistant strains of Mycobacterium …

Drug‐resistant tuberculosis (TB) is a major public health concern and contributes to high
morbidity and mortality. New evidence supports the use of shorter duration, all‐oral …

The current coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) has not only highlighted the vulnerability …

BACKGROUND: The WHO provides standardized outcome definitions for rifampicin-
resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these …

Rationale: Earlier biomarkers of pulmonary tuberculosis (PTB) treatment outcomes are
critical to monitor shortened anti-TB treatment (ATT). Objectives: To identify early …

Background Poor treatment adherence contributes to lower treatment completion and higher
loss to follow-up among people with tuberculosis (PWTB). Medication monitors have shown …

Tuberculosis (TB) treatment requires a long therapeutic duration and induces adverse
effects such as hepatotoxicity, causing discontinuation of treatment. Reduced adherence to …

In many countries where tuberculosis (TB) is endemic, the Bacillus Calmette–Guérin (BCG)
vaccine is given as close to birth as possible to protect infants and children from severe …

Standardised outcome definitions are crucial for monitoring and comparing effectiveness of
treatment strategies for tuberculosis (TB) over time and across geographies. The World …

Tuberculosis (TB) poses significant challenges due to its high transmissibility within
populations and intrinsic resistance to treatment, rendering it a formidable respiratory …